Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 -11.4x EV/EBITDA | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $125m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (55 %) | (32 %) | 949 % | 133 % | 41 % | 31 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (19 %) | (229 %) | (758 %) | (57 %) | (10 %) | 18 % | 28 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (24 %) | (241 %) | (779 %) | (63 %) | (13 %) | 8 % | 27 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 73 % | 165 % | 288 % | 29 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company based in Irvine, California, specializing in developing treatments for diseases with high unmet medical needs. The company primarily focuses on eye care and infectious diseases, with a notable product, XDEMVY (lotilaner ophthalmic solution 0.25%), which is FDA-approved for treating Demodex Blepharitis—a condition affecting the eyelids. Tarsus also has a pipeline of other potential treatments targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea.
Tarsus serves a diverse client base, including healthcare providers, ophthalmologists, and patients suffering from these specific conditions. The company operates in the biopharmaceutical market, which involves the research, development, and commercialization of medical treatments.
The business model of Tarsus is centered around the development and commercialization of its proprietary treatments. They generate revenue through the sale of their FDA-approved products and potentially through future products currently in their pipeline. Additionally, Tarsus engages in strategic partnerships and collaborations to enhance their research capabilities and expand their market reach.
Tarsus has successfully raised funds through multiple private and public financings, which supports their research and development activities. The company is committed to ethical operations and compliance with applicable laws and regulations, ensuring a robust compliance program is in place.
In summary, Tarsus Pharmaceuticals, Inc. is a forward-thinking biopharmaceutical company dedicated to addressing unmet medical needs through innovative treatments, primarily in the eye care and infectious disease sectors.
Keywords: Biopharmaceutical, Eye Care, Infectious Diseases, FDA-approved, Demodex Blepharitis, Research, Development, Healthcare Providers, Compliance, Innovation.